keynote-826: pembrolizumab plus chemotherapy for patients with metastatic cervical cancer
Published 2 years ago • 1K plays • Length 2:26Download video MP4
Download video MP3
Similar videos
-
1:16
keynote 826: pembrolizumab chemo in patients with advanced cervical cancer
-
7:18
keynote-826: pembrolizumab chemotherapy vs placebo chemotherapy for cervical cancer
-
2:26
#esmo21 highlights on pembro chemo in 1st-line metastatic cervical cancer: the keynote-826 study
-
5:13
immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer
-
6:38
pembrolizumab with chemotherapy as first line for metastatic cervical cancer
-
1:14
keynote-a18: pembrolizumab with chemoradiotherapy for advanced cervical cancer
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
1:32:29
candid conversations on modern urothelial cancer management
-
0:46
gynecologic oncology at asco 2022: subgroup analysis of keynote-826
-
7:53
pembrolizumab for persistent, recurrent, or metastatic cervical cancer
-
1:21
keynote-921: pembrolizumab plus docetaxel in chemotherapy-naïve mcrpc
-
1:19
novel immunotherapy-based combination approaches in cervical cancer
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
3:18
gynecologic oncology at esmo congress 2021: trial study in cervical cancer
-
8:06
keytruda treatment of patients with recurrent or metastatic cervical cancer
-
8:20
immune checkpoint inhibitors for endometrial and cervical cancer
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
2:33
pembrolizumab with chemoradiotherapy for cervical cancer
-
4:23
keynote-407: 3-year follow-up of pembrolizumab plus chemo in nsclc